Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
NOVARTIS NEW ZEALAND LIMITED,Secukinumab,"moderate to severe hidradenitis suppurativa, first-line biologic treatment",Secukinumab (COSENTYX),Recommended for decline,Community and Hospital,Dermatologicals
